Hangzhou Diagens Biotechnology Co., Ltd. - B Stock: price and insider trades · Hong Kong
Hangzhou Diagens Biotechnology Co., Ltd. - B: what insiders have been doing
We have very little insider data for Hangzhou Diagens Biotechnology Co., Ltd. - B so far: the most recent filing dates from 14 April 2026. With so few records, no pattern can be drawn yet. Source: insider filings from HKEX. Past trades are no guide to future returns.
Insider Decl.
1
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a
Fundamental score
Ranked 20,493 of 26,897 companies
33.5
score / 100
Value34
Quality33
FCF yld-0.3%
Earn yld-0.3%
EV/EBITDA·
ROE-40%
Gross mgn72%
Net mgn-41%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
HK$232.00
Analyst consensus
Income statement
RevenueHK$164.4M
Gross profitHK$118.1M72% margin
EBITDA-HK$66.6M-40% margin
Net income-HK$67.1M-66.4% margin
Valuation
P/Book22.7x
Balance sheet & cash
Market capHK$20.6B
Total debtHK$5.9M
Free Cash Flow-HK$55M
Debt / Equity7%
Profitability & ownership
ROE-39.5%
ROA-23.5%
% insiders47.4%
% institutions17.4%
Last declaration on 14 April 2026
About Hangzhou Diagens Biotechnology Co., Ltd. - B
Hangzhou Diagens Biotechnology Co., Ltd. is a company focused on developing biopharmaceutical solutions. It is listed on the Hong Kong Stock Exchange.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
